ProBioGen AG

03.01.2019 – 10:01
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals
Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...
mehr
19.04.2007 – 12:35
ProBioGen, Germany and Minapharm, Egypt enter into development and co-promotion agreements
Berlin (ots) - ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co-promotion. In the first agreement, ProBioGen will apply its proven cell generation process for biopharmaceutical cell ...
mehr